Dec. 4, 2020, the day Dr. Amir Barzin first witnessed the Amplitude, was a milestone for the UNC School of Medicine assistant professor.
Barzin, who has also served as incident commander for UNC Health’s Respiratory Diagnostic Center, had been working long hours for weeks with an army of others from around campus to help build from scratch a multifaceted coronavirus testing program on the Carolina campus.
He and his colleagues had found a reliable source for highly accurate nasal-swab tests with the added advantage of not requiring users to shove them deep into the upper reaches of the nasal cavity. They had secured three on-campus sites for sample collection and were developing a system for safely moving people in and out in mere minutes. Meanwhile, more than four dozen people from Information Technology Services and the Hussman School of Journalism and Media were working out the kinks on a web-based application called HallPass to securely and efficiently manage the data flow.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion .
Genetic Technologies LtdJanuary 21, 2021 GMT
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
Key Highlights
Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data
Global Point of Care Infectious Disease Diagnostics Market – InsightsPoint-of-care (POC) diagnostic testing allows patient diagnoses in the physician’s office, home, an ambulance, the field, or in the hospital. POC allows rapid and timely treatment to patient. Infectious diseases often need to be diagnosed early, as.
Natera Files Patent Infringement Suit Against Inivata
News provided by
Share this article
Share this article
SAN CARLOS, Calif., Jan. 20, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned subsidiary Inivata, Inc. for alleged infringement of Natera s U.S. Patent Nos. 10,262,755 and 10,597,709. These patents protect Natera s intellectual property in the fields of personalized monitoring and molecular residual disease (MRD) testing in oncology.
Natera s complaint alleges that Inivata infringes these patents by selling, manufacturing, and/or using various oncology products, including those in the MRD testing and liquid biopsy spaces. Natera is seeking both injunctive relief and monetary damages.